Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:35 2024-04-19 am EDT 5-day change 1st Jan Change
19.88 HKD +0.51% Intraday chart for Sinopharm Group Co. Ltd. +2.26% -2.79%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator MT
Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue MT
Sinopharm Group Co. Ltd. Proposes Final Dividend of for the Financial Year Ended 31 December 2023, Payable on 13 August 2024 CI
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings MT
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6% MT
US Inflation, Light News Flow Churns Asian Stock Markets MT
Sinopharm Group Co. Ltd. Announces Change of Registered Address CI
Nomura Adjusts Sinopharm Group’s Price Target to HK$32.39 Form HK$33.31, Keeps at Buy MT
China Traditional Chinese Medicine's Stock Bolts on Privatization Offer MT
China stocks extend gains led by coal, AI; HK shares up RE
Hong Kong Stocks Hover Near Two-Month Highs Amid Mixed Corporate Earnings MT
China stocks jump with AI shares leading on Nvidia forecast; HK shares flat RE
Sinopharm offers to take China-TCM private in nearly $3 bln deal RE
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation MT
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan MT
Sinopharm to Renew Financial Services Deal with Affiliate MT
Hutchmed China renews deals with "substantial" shareholders AN
Wenzhou Kangning Hospital Inks Sale, Lease Back Deal With Sinopharm Holding MT
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets MT
Interest Rates, Earnings, FX Roil Asian Stock Markets MT
Linklogis to Offload Entire 19.6% Stake in Pharma Supply Chain Financing Associate MT
Chart Sinopharm Group Co. Ltd.
More charts
Sinopharm Group Co Ltd is a China-based company principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is engaged in the operation of chain pharmacy stores. Other Business segment is engaged in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
18.37 CNY
Average target price
25.06 CNY
Spread / Average Target
+36.39%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 1099 Stock
  4. News Sinopharm Group Co. Ltd.
  5. Wenzhou Kangning Hospital Inks Sale, Lease Back Deal With Sinopharm Holding